Search results for "Intensive Care"

showing 10 items of 2793 documents

Alzheimer's disease: Only prevention makes sense

2018

Alzheimer's disease therapeutics is one of the most important endeavours in today's clinical investigation. Over more than 30 years of research, no disease-modifying treatment has been approved by either the FDA or the EMA to treat Alzheimer's disease. Recently, the evidence of pathological alterations in the brain tissue has been gathered showing that the signs of brain damage appear more than 20 years before the onset of Alzheimer's dementia. The major aim of this review is to underpin the idea that in Alzheimer's therapeutics, only prevention makes sense. It is difficult to visualise that would-be patients may be treated with endovenous administration of antibodies for several years to d…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryBrain damageDiseaseBiochemistryAsymptomaticAntioxidantsMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseAnimalsHumansVitamin EMedicineDementiaHealthy LifestyleTreatment FailureIntensive care medicinePathologicalNootropic AgentsAgedAged 80 and overClinical Trials as Topicbusiness.industryAntibodies MonoclonalCognitionGeneral MedicineMiddle Agedmedicine.diseaseClinical trialDisease Models Animal030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryMinimal cognitive impairmentEuropean Journal of Clinical Investigation
researchProduct

Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure

2019

> You wouldn't wear just any pair of glasses—your prescription is tailored to your vision. This statement was made by President Obama in 2016 during the presentation and launch of the Precision Medicine Initiative. Whether we like it or not (and some politicians today seem rather indifferent), we are headed toward a new paradigm of precision medicine. This is a new era of medicine in which the right treatment is delivered at the right time to the right person. In the context of heart failure (HF)5 there is a long road ahead to fully realize the goals of precision medicine. HF is a complex syndrome with heterogeneous pathophysiology. Most medical treatments currently used in HF have been tes…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryContext (language use)030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumansIn patientPrecision MedicineMedical prescriptionIntensive care medicineHeart FailureEjection fractionbusiness.industryBiochemistry (medical)Precision medicinemedicine.disease030104 developmental biologyHeart failureBiomarker (medicine)NeprilysinbusinessBiomarkersClinical Chemistry
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease

2018

Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and …

0301 basic medicinemedicine.medical_specialtyConsensusDelphi study; Gaucher disease; Management goals; PROMs; TherapyDelphi methodEarly detectionGaucher diseaseDiseasePROMs03 medical and health sciences0302 clinical medicineQuality of life (healthcare)HumansMedicineIntensive care medicineSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSManagement goalsbusiness.industryDisease ManagementType 1 Gaucher DiseaseExpert consensus[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologySocial engagementDelphi study3. Good healthEurope030104 developmental biology030220 oncology & carcinogenesisQuality of LifePhysical therapyMolecular MedicineTherapybusinessBlood Cells, Molecules, and Diseases
researchProduct

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

2019

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low …

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismOsteoporosis030209 endocrinology & metabolismBone resorption makerAsia pacific regionCollagen Type IBone remodeling03 medical and health sciences0302 clinical medicineN-terminal telopeptideBone DensityOsteoporosis treatmentHealth caremedicineHumansRadiology Nuclear Medicine and imagingOrthopedics and Sports MedicineIntensive care medicineReimbursementAnabolicsBone mineralddc:616Hip Fracturesbusiness.industryAnti-resorptivesmedicine.diseasePeptide FragmentsBone formation makerOsteoporosisBone Remodeling030101 anatomy & morphologybusinessBiomarkersProcollagen
researchProduct

The role of immunogenetics in covid‐19

2021

Coronavirus disease 2019 (COVID-19) is induced by SARS-CoV-2 and may arise as a variety of clinical manifestations, ranging from an asymptomatic condition to a life-threatening disease associated with cytokine storm, multiorgan and respiratory failure. The molecular mechanism behind such variability is still under investigation. Several pieces of experimental evidence suggest that genetic variants influencing the onset, maintenance and resolution of the immune response may be fundamental in predicting the evolution of the disease. The identification of genetic variants behind immune system reactivity and function in COVID-19 may help in the elaboration of personalized therapeutic strategies…

0301 basic medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ReviewDiseaseImmunogeneticsHuman leukocyte antigenSeverity of Illness IndexCatalysisSARS‐CoV‐2ABO Blood-Group SystemInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineCOVID‐19HLA AntigensmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseGenetic variabilityPhysical and Theoretical ChemistryIntensive care medicineMolecular Biologylcsh:QH301-705.5SpectroscopyAB0business.industrySARS-CoV-2Organic ChemistryImmunityCOVID-19General MedicineImmunosenescencemedicine.disease3. Good healthComputer Science ApplicationsKIRHLA030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisIdentification (biology)Disease SusceptibilityCytokine stormbusiness
researchProduct

Development of artemisinin resistance in malaria therapy

2019

Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on…

0301 basic medicinemedicine.medical_specialtyDrug ResistanceAntimalarials03 medical and health sciences0302 clinical medicineChloroquineparasitic diseasesAsian countryAnimalsHumansMedicineArtemisininIntensive care medicinePharmacologyPolymorphism Geneticbusiness.industryMefloquineArtemisinin resistancemedicine.diseaseArtemisininsTreatment efficacyMalariaFirst line treatment030104 developmental biology030220 oncology & carcinogenesisMutationbusinessMalariamedicine.drugPharmacological Research
researchProduct

Should we administer antifungal drugs before the diagnosis of invasive fungal infection in non-neutropenic critically ill patients?

2016

0301 basic medicinemedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain MedicineCritically illbusiness.industryAntifungal drugsAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE First Round030106 microbiologysepsis fungal infectionNon neutropenic03 medical and health sciencesAnesthesiology and Pain Medicine0302 clinical medicineEmergency Medicinemedicine030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct

An "aubergine" in the heart: huge native mitral valve endocarditis caused by Streptococcus agalactiae.

2017

0301 basic medicinemedicine.medical_specialtyFever030106 microbiologyMEDLINE030204 cardiovascular system & hematologymedicine.disease_causeStreptococcus agalactiae03 medical and health sciencesMitral valve endocarditis0302 clinical medicineStreptococcal InfectionsInternal MedicinemedicineHumansIntensive care medicineEndocarditisbusiness.industryMiddle AgedDyspneaStreptococcus agalactiaeItalyEchocardiographyEmergency MedicineChordae TendineaeMitral ValveFemalebusinessEmergency Service HospitalInternal and emergency medicine
researchProduct